Bioden Idec in three-year Edinburgh University deal

Share this article
Have your say

AMERICAN life sciences giant Biogen Idec has sealed a three-year deal with Edinburgh University to develop drugs to treat multiple sclerosis (MS) and motor neuron disease.

The university remained tight-lipped over how much cash the Massachusetts-based company was contributing to the partnership, which will involve staff from the Edinburgh BioQuarter, the commercialisation service and science park built next to the Edinburgh Royal Infirmary.

Siddharthan Chandran, professor of neurology, said: “This landmark partnership is a brilliant example of academic-industrial collaboration in the field of discovery science.”

Signing up Biogen Idec is the latest in a string of partnership deals for the BioQuarter, which have included GlaxoSmithKline, Galapagos and Galecto Biotech.